We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

4 hedge funds and large institutions have $164K invested in Scinai Immunotherapeutics in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.24% less ownership

Funds ownership: 0.39% → 0.15% (-0.24%)

20% less funds holding

Funds holding: 5 → 4 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

55% less capital invested

Capital invested by funds: $367K → $164K (-$203K)

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
+$7.36K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$177K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$83K
3
TRCT
Tower Research Capital (TRC)
New York
-$1K

SCNI Hedge Fund Activity: Q2 2017 in Review

4 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2017, worth a combined $164K — down 55% from $367K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of SCNI and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Wells Fargo, opening a new position worth an estimated $7.36K. The largest seller was Citadel Advisors, exiting entirely with an estimated $177K sold.

  • 4 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2017, down from 5 in Q1 2017.
  • Funds reported $164K of Scinai Immunotherapeutics stock for Q2 2017, down 55% quarter-over-quarter.
  • 1 fund opened new Scinai Immunotherapeutics positions in Q2 2017 and 2 closed out, a net change of -1 holder.
  • The largest Scinai Immunotherapeutics buyer in Q2 2017 was Wells Fargo, an estimated $7.36K added.
  • The largest Scinai Immunotherapeutics seller in Q2 2017 was Citadel Advisors, an estimated $177K sold.

Based on aggregated 13F filings for Q2 2017.